Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 7.49M | 7.50M | 686.00K | 284.00K | 110.00K |
Gross Profit | 7.39M | 7.50M | 260.45K | -121.98K | 25.23K |
EBITDA | -3.11B | -8.50M | -10.67M | -10.02M | -8.79M |
Net Income | -3.07B | -8.97M | -11.28M | -10.68M | -8.94M |
Balance Sheet | |||||
Total Assets | 3.96B | 7.36M | 5.12M | 7.17M | 10.20M |
Cash, Cash Equivalents and Short-Term Investments | 1.05B | 4.55M | 1.80M | 3.49M | 8.04M |
Total Debt | 577.86M | 555.51K | 885.95K | 7.73M | 992.02K |
Total Liabilities | 1.73B | 1.66M | 2.20M | 43.43M | 35.97M |
Stockholders Equity | 2.23B | 5.70M | 2.91M | -36.26M | -25.77M |
Cash Flow | |||||
Free Cash Flow | -3.08B | -10.23M | -7.68M | -8.51M | -8.52M |
Operating Cash Flow | -3.08B | -10.22M | -7.36M | -8.35M | -8.07M |
Investing Cash Flow | -21.95M | -379.25K | -318.26K | -336.76K | -652.27K |
Financing Cash Flow | 1.76B | 13.36M | 5.98M | 4.13M | 992.86K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.92B | -0.43 | -41.67% | 2.21% | 22.29% | -1.85% | |
45 Neutral | $381.87K | ― | -89.21% | ― | -100.00% | 96.37% | |
45 Neutral | $3.77M | ― | -248.95% | ― | ― | 98.45% | |
44 Neutral | $4.76M | ― | -473.31% | ― | -100.00% | 95.01% | |
30 Underperform | $2.42M | ― | -660.37% | ― | ― | 74.27% | |
29 Underperform | $8.54M | ― | -212.38% | ― | ― | 57.99% | |
27 Underperform | $2.69M | ― | -512.79% | ― | ― | 31.66% |
On August 26, 2025, Azitra, Inc. entered into a Modification Agreement with Alumni Capital LP to amend terms of a previous Purchase Agreement. This allows Azitra to sell up to $20 million of its common stock to Alumni Capital, with specific options for determining the purchase price. The agreement provides flexibility in stock sales, potentially impacting Azitra’s financial strategy and market operations.
On August 20, 2025, Azitra, Inc. filed a certificate of amendment to implement a 1-for-6.66 reverse stock split of its common stock, following approval by its stockholders earlier in February 2025. This reverse stock split will take effect on August 21, 2025, and the company’s stock will begin trading on a split-adjusted basis on the NYSE American. The reverse stock split aims to consolidate every 6.66 shares into one, without affecting the par value or other terms of the common stock, and stockholders entitled to fractional shares will receive cash payments instead.
On July 3, 2025, Azitra, Inc. held a reconvened annual meeting of stockholders where they approved an amendment to the company’s Certificate of Incorporation to increase the authorized common stock shares from 100 million to 200 million. This decision, which was initially proposed on June 23, 2025, and required additional time for voting, reflects a strategic move to potentially enhance the company’s capital structure and market positioning.
On June 23, 2025, Azitra, Inc. held its annual meeting of stockholders where a quorum was achieved with proxies from over one-third of the shares. The meeting resulted in the approval of the election of four directors and the ratification of Grassi & Co. as the independent accounting firm for 2025. Additionally, stockholders approved the issuance of more than 19.99% of the company’s shares under a purchase agreement with Alumni Capital LP. However, voting on a proposal to increase the authorized shares was adjourned to July 3, 2025, to allow more time for stockholder participation.
Azitra, Inc. announced updates to its 2025 Annual Meeting of Stockholders, scheduled for June 23, 2025. The company aims to amend its Certificate of Incorporation to increase its authorized common stock from 100 million to 200 million shares, following changes in the Delaware General Corporation Law affecting voting standards. This move reflects Azitra’s strategic positioning to potentially expand its market presence and operational capacity.
On June 17, 2025, Azitra, Inc. announced promising safety data from its Phase 1b clinical trial for ATR12-351, a live biotherapeutic candidate targeting Netherton syndrome. The trial, which is halfway enrolled, showed that ATR12-351 was generally safe and well-tolerated, with only mild to moderate application site reactions reported. This milestone marks significant progress in Azitra’s mission to bring ATR12-351 to market, potentially offering a life-changing treatment for those affected by this rare skin condition.